Amino Acid Solution 5.9% with Electrolytes
Lipid Emulsion 12.5%
12.5%
500 ml
155 ml
221 ml
124 ml
Appearance before reconstitution:
Appearance after reconstitution:
The three-chambered pouch is a multi-layer plastic pouch.
To prevent air contact, Numeta is packaged in an oxygen barrier overpouch containing a sticker with an oxygen absorber and an oxygen indicator.
Package Sizes
500 ml pouch: 6 units per carton
1 x 500 ml pouch
Only certain package sizes may be marketed.
Marketing Authorization Holder and Responsible Manufacturer
Marketing Authorization Holder
Baxter, S.L.
Pouet de Camilo 2, 46394 Ribarroja del Turia (Valencia)
Responsible Manufacturer
Baxter S.A.
Boulevard Rene Branquart, 80
7860 Lessines
Belgium
This medicinal product is authorized in the Member States of the European Economic Area with the following names:
Austria Germany | NumetaG16 % E Emulsion zur Infusion |
Belgium Luxembourg | Numetzah G16%E,émulsion pour perfusion |
France | Numetah G16 %E émulsion pour perfusion |
Denmark Norway Sweden | NumetaG16E |
Czech Republic Greece | NumetaG16 % E |
Netherlands | NumetaG16%E emulsie voor infusie |
Ireland United Kingdom | NumetaG16%E, Emulsion for Infusion |
Italy | NumetaG16%E emulsione per infusione |
Finland | NumetaG16E infuusioneste, emulsio |
Poland | NumetaG16 % E |
Portugal | NumetaG16%E |
Spain | NumetaG16%E, emulsión para perfusión |
Last Review Date of this Leaflet: May 2024
The detailed and updated information on this medicinal product is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/
---------------------------------------------------------------------------------------------------------------------
This information is intended solely for healthcare professionals:*
(*) Please note that in certain cases, these medicines may be administered at home by parents or other caregivers. In these cases, parents/caregivers should read the following information.
Do not add any medication to the pouch without first checking compatibility.Particulates may form or the lipid emulsion may break down, which could block blood vessels.
Numeta G16%E must be at room temperature before use.
Before administering Numeta G16%E, you must prepare the pouch as described below.
Ensure the pouch is not damaged and use it only if it is not damaged.A non-damaged pouch has the following appearance:
Before opening the overpouch, examine the color of the oxygen absorber.
Figures 1 and 2 illustrate how to remove the overpouch. Dispose of it along with the oxygen indicator and absorber.
Figure 1Figure 2
Pouch Preparation
Activating the 3-chamber pouch (breaking the two non-permanent seals)
Step 1: Roll the pouch from the D-loop side.
Step 2: Press until the non-permanent seals open.
Step 3: Change direction and roll the pouch towards the D-loop until the seal is completely open. Follow the same steps to open the second non-permanent seal.
Step 4: Turn the pouch back at least three times to mix the contents well. The appearance of the mixed solution should be a white and milky emulsion.
Step 5: Remove the protective cap from the administration port and insert the intravenous administration equipment.
Activating the 2-chamber pouch (breaking the non-permanent seal between the amino acid and glucose chambers)
Step 1: To break only the amino acid/glucose seal, start rolling the pouch from the D-loop side of the seal separating the amino acid and glucose chambers and press to open the seal separating both compartments.
Step 2: Place the pouch so that the lipid emulsion chamber is facing the operator and roll the pouch while protecting the lipid emulsion chamber with your palms.
Step 3: With one hand, apply pressure by rolling the pouch towards the tubes.
Step 4: Next, change direction and roll the pouch towards the D-loop, pressing with the other hand until the seal separating the amino acid and glucose solutions is completely open.
Step 5: Turn the pouch back at least three times to mix the contents well. The appearance of the mixed solution should be transparent, colorless, or slightly yellowish.
Step 6: Remove the protective cap from the administration port and insert the intravenous administration equipment.
The administration rate should be gradually increased during the first hour and adjusted according to the following factors:
The dose to be administered
The daily fluid intake
The duration of the infusion.
Administration Form
When used in newborns and children under 2 years, the emulsion (in the pouch and in the administration equipment) should be protected from light exposure until the end of administration.
It is recommended to use a 1.2-micron filter for the administration of Numeta G16%E.
Due to its high osmolarity, Numeta G16%E can only be administered undiluted through a central vein; however, a suitable dilution of Numeta G16%E with water for injection reduces the osmolarity and allows peripheral infusion.
The following formula indicates the impact of dilution on the osmolarity of the pouches.
Osmolarity final | = | Volumen de la bolsa x osmolaridad inicial |
Agua añadida + Volumen de la bolsa |
The following table shows examples of osmolarity for the 2- and 3-chamber pouches activated after adding water for injection:
Amino Acids and Glucose (B2C activated) | Amino Acids, Glucose, and Lipids (B3C activated) | |
Volumen inicial en la bolsa (ml) | 376 | 500 |
Osmolaridad inicial (mOsm/l aprox) | 1585 | 1230 |
Volumen de agua añadido (ml) | 376 | 500 |
Volumen final tras adición (ml) | 752 | 1000 |
Osmolaridad tras adición (mOsm/l aprox) | 792,5 | 615 |
Adding Medication
The mixtures containing oligoelements and vitamins should be protected from light, from the administration point and during administration. Exposure to ambient light generates peroxides and other degradation products that can be reduced with photoprotection.
Medicaments compatible with the product can be added to the reconstituted mixture (after opening the non-permanent seals and mixing the contents of the two or three chambers) through the administration port.
Vitamins can also be added to the glucose chamber before reconstituting the mixture (before opening the non-permanent seals and mixing the solutions and emulsion).
Tables 1-6 show the possible additions of commercially available oligoelement solutions (identified as TE1, TE2, and TE4), vitamins (identified as lyophilized V1 and emulsion V2), and electrolytes in defined quantities.
1Compatibility with TE4, V1, and V2
Table 1: Compatibility of 3-in-1 (B3C activated) with or without dilution in water
For 500 ml (3-in-1 mixture with lipids) | ||||||
Undiluted mixture | Diluted mixture | |||||
Aditivos | Nivel incluido | Adición máxima | Nivel | Nivel incluido | Adición máxima | Nivel |
Sodio (mmol) | 12,0 | 25,6 | 37,6 | 12,0 | 25,6 | 37,6 |
Potasio (mmol) | 11,4 | 26,2 | 37,6 | 11,4 | 26,2 | 37,6 |
Magnesio (mmol) | 1,6 | 3,6 | 5,2 | 1,6 | 3,6 | 5,2 |
Calcio (mmol) | 3,1 | 16,4 | 19,5 | 3,1 | 8,2 | 11,3 |
Fosfato* (mmol) | 4,4 | 6,9 | 11,3 | 4,4 | 6,9 | 11,3 |
Oligoelementos y vitaminas | - | 10 ml TE4 + | 10 ml TE4 + | - | 5 ml TE4 | 5 ml TE4 |
Agua para preparaciones inyectables | - | - | - | - | 350 ml | 350 ml |
* Fosfato orgánico
Table 2: Compatibility of 2-in-1 (B2C activated) with or without dilution in water
For 376 ml (2-in-1 mixture without lipids) | ||||||
Undiluted mixture | Diluted mixture | |||||
Aditivos | Nivel incluido | Adición máxima | Nivel | Nivel incluido | Adición máxima | Nivel |
Sodio (mmol) | 11,6 | 26,0 | 37,6 | 11,6 | 0,0 | 11,6 |
Potasio (mmol) | 11,4 | 26,2 | 37,6 | 11,4 | 0,0 | 11,4 |
Magnesio (mmol) | 1,6 | 3,6 | 5,2 | 1,6 | 0,0 | 1,6 |
Calcio (mmol) | 3,1 | 8,2 | 11,3 | 3,1 | 0,0 | 3,1 |
Fosfato* (mmol) | 3,2 | 8,1 | 11,3 | 3,2 | 0,0 | 3,2 |
Oligoelementos y vitaminas | - | 5ml TE4 | 5ml TE4 | - | 5ml TE4 | 5ml TE4 |
Agua para preparaciones inyectables | - | - | - | - | 450 ml | 450 ml |
* Fosfato orgánico
2Compatibility with TE1, V1, and V2
Table 3: Compatibility of 3-in-1 (B3C activated) with or without dilution in water
For 500 ml (3-in-1 mixture with lipids) | ||||||
Undiluted mixture | Diluted mixture | |||||
Aditivos | Nivel incluido | Adición | Nivel | Nivel incluido | Adición máxima | Nivel |
Sodio (mmol) | 12,0 | 4,0 | 16,0 | 12,0 | 0,0 | 12,0 |
Potasio (mmol) | 11,4 | 6,2 | 17,6 | 11,4 | 0,0 | 11,4 |
Magnesio (mmol) | 1,6 | 1,6 | 1,6 | 0,0 | 1,6 | |
Calcio (mmol) | 3,1 | 2,1 | 5,2 | 3,1 | 0,0 | 3,1 |
Fosfato* (mmol) | 4,4 | 2,0 | 6,4 | 4,4 | 0,0 | 4,4 |
Oligoelementos y vitaminas | - | 5 ml TE1 + 5 ml V2 | 5 ml TE1 + 5 ml V2 | - | 5 ml TE1 + 5 ml V2 | 5 ml TE1 + 5 ml V2 |
Agua para preparaciones inyectables | - | - | - | - | 350 ml | 350 ml |
* Fosfato orgánico
Table 4: Compatibility of 2-in-1 (B2C activated) with or without dilution in water
For 376 ml (2-in-1 mixture without lipids) | ||||||
Undiluted mixture | Diluted mixture | |||||
Aditivos | Nivel incluido | Adición máxima | Nivel | Nivel incluido | Adición máxima | Nivel |
Sodio (mmol) | 11,6 | 26,0 | 37,6 | 11,6 | 0,0 | 11,6 |
Potasio (mmol) | 11,4 | 26,2 | 37,6 | 11,4 | 0,0 | 11,4 |
Magnesio (mmol) | 1,6 | 3,6 | 5,2 | 1,6 | 0,0 | 1,6 |
Calcio (mmol) | 3,1 | 8,2 | 11,3 | 3,1 | 0,0 | 3,1 |
Fosfato* (mmol) | 3,2 | 8,1 | 11,3 | 3,2 | 0,0 | 3,2 |
Oligoelementos y vitaminas | - | 5 ml TE1 | 5 ml TE1 | - | 5 ml TE1 | 5 ml TE1 |
Agua para preparaciones inyectables | - | - | - | - | 450 ml | 450 ml |
* Fosfato orgánico
3Compatibility with TE2, V1, and V2
Table 5: Compatibility of 3-in-1 (B3C activated) with or without dilution in water
For 500 ml (3-in-1 mixture with lipids) | ||
Undiluted mixture | Diluted mixture | |
Страна регистрации Активное вещество AlaninaArgininaAspartico acidoCisteinaGlutamico acidoGlicinaHistidinaIsoleucinaLeucinaLisina monohidratoLisinaMetioninaOrnitina hidrocloruroOrnitinaFenilalaninaProlinaSerinaTaurinaTreoninaL-triptofanoTirosinaValinaSodio cloruroAcetato potasioCalcio cloruro dihidratoAcetato magnesio tetrahidratoGlicerofosfato sodioGlucosa monohidratoGlucosa anhidraAceite de soja aceite de oliva Требуется рецепт Да Производитель Состав Glicerol (e 422) (14,10 g mg),
Oleato de sodio (0,19 g mg),
Hidroxido de sodio (e 524) (C.S. - mg) Информация носит справочный характер и не является медицинской рекомендацией. Перед приёмом любых препаратов проконсультируйтесь с врачом. Oladoctor не несёт ответственности за медицинские решения, принятые на основе этого контента. Общайтесь с врачом онлайнЕсть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода. Смотреть всех врачей |